Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Co-Diagnostics Inc is a diagnostics & research business based in the US. Co-Diagnostics shares (CODX) are listed on the NASDAQ and all prices are listed in US Dollars. Co-Diagnostics employs 39 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $8.48 |
|---|---|
| 52-week range | $7.01 - $20.69 |
| 50-day moving average | $8.96 |
| 200-day moving average | $9.03 |
| Wall St. target price | $19.33 |
| PE ratio | 6.2219 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $1.42 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.48 from 2022-01-18
| 1 week (2022-01-12) | -10.64% |
|---|---|
| 1 month (2021-12-17) | -2.08% |
| 3 months (2021-10-19) | -0.70% |
| 6 months (2021-07-19) | -1.62% |
| 1 year (2021-01-19) | -28.23% |
|---|---|
| 2 years (2020-01-17) | 678.05% |
| 3 years (2019-01-18) | 624.79% |
| 5 years (2017-01-15) | N/A |
Valuing Co-Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Co-Diagnostics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Co-Diagnostics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Co-Diagnostics shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Co-Diagnostics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $52.1 million.
The EBITDA is a measure of a Co-Diagnostics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $104.6 million |
|---|---|
| Operating margin TTM | 49.49% |
| Gross profit TTM | $58 million |
| Return on assets TTM | 40.46% |
| Return on equity TTM | 54.88% |
| Profit margin | 40.11% |
| Book value | $3.47 |
| Market capitalisation | $258.4 million |
TTM: trailing 12 months
We're not expecting Co-Diagnostics to pay a dividend over the next 12 months.
Over the last 12 months, Co-Diagnostics's shares have ranged in value from as little as $7.01 up to $20.685. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Co-Diagnostics's is -1.8995. This would suggest that Co-Diagnostics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Co-Diagnostics has bucked the trend.
Co-Diagnostics, Inc. , a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
